BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
23
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYNLONTA (loncastuximab tesirine) is an antibody-drug conjugate (ADC) that combines an anti-CD19 monoclonal antibody with a cytotoxic payload. It is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have received at least two prior therapies. The drug works by targeting CD19-expressing B-cell malignancies and delivering cytotoxic agents directly to cancer cells.
$0.675MPart D
PeakProduct is in peak commercial phase with modest Medicare spending, indicating an established but niche market with sustained team investments in medical affairs and commercial operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (23)
Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
Started Nov 2026
23 enrolled
Post-transplant Lymphoproliferative Disorder
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Started Jan 2026
26 enrolled
Large B-cell LymphomaRelapseDLBCL+1 more
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Started Oct 2025
120 enrolled
Aggressive Diffuse Large B-cell LymphomaHigh-grade B-cell Lymphoma (HGBL)Follicular Lymphoma (FL) Grade 3B
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
Started Aug 2025
29 enrolled
Relapsed or Refractory Large B-cell Lymphoma
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
Started Mar 2025
12 enrolled
Central Nervous System Lymphoma
Worked on ZYNLONTA at ADC Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.